Drugs / Brivekimig
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07170917 | Nov 2025 → Aug 2027 expected | hidradenitis suppurativa | Sanofi | Recruiting | No outcome recorded |
| Phase 2 | NCT06975722 | Jul 2025 → Dec 2026 expected | ulcerative colitis | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06958536 | Jun 2025 → Dec 2026 expected | Crohn disease | Sanofi | Recruiting | No outcome recorded |
| Phase 2 | NCT06812988 | Feb 2025 → Apr 2027 expected | type 1 diabetes mellitus | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06500702 | Dec 2024 → Dec 2026 expected | focal segmental glomerulosclerosis, minimal change disease | Sanofi | Recruiting | No outcome recorded |
| Phase 2 | NCT05849922 | Jun 2023 → Aug 2024 | hidradenitis suppurativa | Sanofi | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-17 | Sanofi | Results Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study sanofi.com ↗
In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary endpoints in biologic-naïve patients compared to placebo at week 16 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-17 | Sanofi | Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study sanofi.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Brivekimig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07170917 ↗ |
| Known as | SAR442970 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06975722 ↗ |
| Action | Inhibit | “Anti-TNF-OX40L” NCT05849922 ↗ |
| Modality | Protein / enzyme biologic | “NANOBODY® Molecule” NCT06812988 ↗ |
| Route | Subcutaneous | “Pharmaceutical form: Solution Route of administration: Subcutaneous injection” NCT06812988 ↗ |